mardi 26 janvier 2021


Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Par Rédaction , dans Communiqués , le 15 octobre 2018

Monday, October 15th 2018 at 8:30pm UTC

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR T
(AlloCAR T™) therapies for cancer, today announced the closing of its
previously announced initial public offering of 20,700,000 shares of its
common stock, which includes 2,700,000 shares sold pursuant to the
exercise in full by the underwriters of their option to purchase
additional shares, at a price to the public of $18.00 per share.
Including the option exercise, the gross proceeds to Allogene
Therapeutics from the offering, before deducting the underwriting
discounts and commissions and offering expenses, were $372.6 million.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Cowen and Company,
LLC and Jefferies LLC acted as the joint book-running managers for the
offering.

The offering was made only by means of a prospectus. Copies of the final
prospectus related to the offering may be obtained from:

  • Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West
    Street, New York, NY 10282, or via telephone: 1-866-471-2526, or via
    email: prospectus-ny@ny.email.gs.com;
    or
  • J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
    Long Island Avenue, Edgewood, NY 11717, or via telephone:
    1-866-803-9204; or
  • Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long
    Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or via
    email: PostSaleManualRequests@broadridge.com;
    or
  • Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520
    Madison Avenue, 2nd Floor, New York, NY 10022, or via telephone:
    1-877-547-6340, or via email: Prospectus_Department@Jefferies.com.

Registration statements relating to these securities have been filed
with the Securities and Exchange Commission and became effective on
October 10, 2018. This press release shall not constitute an offer to
sell or a solicitation of an offer to buy, nor shall there be any sale
of these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.

About Allogene Therapeutics

Allogene Therapeutics, with headquarters in South San Francisco, is a
clinical stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies for
cancer.

Contacts

Allogene Media/Investor Contact:
Christine Cassiano,
714-552-0326
Chief Communications Officer
Christine.Cassiano@allogene.com

Source: Allogene Therapeutics, Inc.

Étiquettes :